Biohaven Ltd. BHVN
Set alert
15.42 USD -1.07 -6.49%
At close
15.15 -0.27 -1.75%
Pre-market · Nov 2, 4:23 AM ET
15.12 Day range 16.33
7.48 52-week range 18.24
- YTD
- +36.58%
- 1 year
- -11.33%
- Open
- 15.46
- Prev close
- 16.49
- Mkt cap
- 2.33B
- Vol
- 3.16M
- Avg vol
- 3.16M
- EPS
- -3.77
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.12
- High
- 16.33
- Forward P/E
- -8.84
- Beta
- 3.20
- Short ratio
- 7.20
- Inst. own
- 95.75%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 1, 2027
- 50-d avg
- 13.59
- 200-d avg
- 12.21
- 1y target
- 22.93
MAX chart
Events in this range
- Nov 10, 2025Earnings: -1.64; estimate -1.91; surprise 14.14%
- Mar 2, 2026Earnings: -1.21; estimate -1.22; surprise 0.82%
- May 4, 2026Earnings: -0.88; estimate -0.86; surprise -2.33%
- Jun 29, 2026Downgrade: B of A Securities · Neutral → Underperform
- Aug 10, 2026Earnings: -0.91; estimate -0.76098; surprise -19.58%
- Aug 11, 2026Rating: RBC Capital · Outperform → Outperform
- Aug 12, 2026Rating: Morgan Stanley · Overweight → Overweight
- Sep 8, 2026Downgrade: RBC Capital · Outperform → Sector Perform
- Sep 10, 2026Rating: HC Wainwright & Co. · Neutral → Neutral
- Oct 23, 2026Rating: RBC Capital · Sector Perform → Sector Perform
- Oct 29, 2026Earnings: -0.86; estimate -0.78333; surprise -9.79%
Signals (68)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 19, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 5, 2026 | 4 weeks ago |
| MACD: Sell Signal | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| SMA: Bullish | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| SMA: Bullish | May 25, 2026 | 5 months ago |
| SMA: Bullish | May 25, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 30, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 23, 2026 | 7 months ago |
| SMA: Bearish | Feb 9, 2026 | 8 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| SMA: Bullish | Jan 19, 2026 | 9 months ago |
| SMA: Bullish | Dec 29, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 8, 2025 | 10 months ago |
| MACD: Sell Signal | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| RSI: Oversold | Nov 3, 2025 | 12 months ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| SMA: Bearish | Sep 8, 2025 | 1 year ago |
| SMA: Bullish | Jul 28, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 7, 2025 | 1 year ago |
| RSI: Oversold | May 12, 2025 | 1 year ago |
| RSI: Oversold | Apr 21, 2025 | 1 year ago |
| RSI: Oversold | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Feb 17, 2025 | 1 year ago |
| SMA: Bullish | Feb 10, 2025 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 2, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Sep 23, 2024 | 2 years ago |
| SMA: Bullish | Sep 16, 2024 | 2 years ago |
| SMA: Bearish | Sep 2, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 19, 2024 | 2 years ago |
| SMA: Bullish | Jul 8, 2024 | 2 years ago |
| SMA: Bearish | Apr 15, 2024 | 2 years ago |
| SMA: Bearish | Apr 15, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 8, 2024 | 2 years ago |
| RSI: Overbought | Dec 11, 2023 | 2 years ago |
| MACD: Buy Signal | Oct 2, 2023 | 3 years ago |
| SMA: Bullish | Sep 25, 2023 | 3 years ago |
| SMA: Bullish | Sep 25, 2023 | 3 years ago |
| SMA: Bearish | Sep 18, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 7, 2023 | 3 years ago |
| SMA: Bearish | Jul 24, 2023 | 3 years ago |
| RSI: Overbought | Jul 10, 2023 | 3 years ago |
| MACD: Buy Signal | May 29, 2023 | 3 years ago |
| RSI: Overbought | May 29, 2023 | 3 years ago |
| SMA: Bullish | May 22, 2023 | 3 years ago |
| SMA: Bullish | May 15, 2023 | 3 years ago |
| SMA: Bearish | May 8, 2023 | 3 years ago |
| SMA: Bullish | May 1, 2023 | 3 years ago |
| SMA: Bearish | Apr 24, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| SMA: Bearish | Feb 20, 2023 | 3 years ago |
| SMA: Bullish | Jan 9, 2023 | 3 years ago |
| RSI: Overbought | Jan 9, 2023 | 3 years ago |
| SMA: Bearish | Dec 19, 2022 | 3 years ago |
Key statistics
- Market cap
- 2.32B
- Enterprise value
- 2.52B
- Trailing P/E
- 0.00
- Forward P/E
- -8.84
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 39.23
- EPS (TTM)
- -4.56
- Beta
- 3.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -256.22M
- Total cash
- 267.87M
- Total debt
- 297.04M
- Return on equity
- -799.46%
- Shares outstanding
- 151.04M
- Short % of float
- 15.16%
- 50-day average
- 13.59
- 200-day average
- 12.21
Analyst view
Consensus: buy
Buy
Price target (mean) 22.93 +48.7% upside
Now 15.42
- Target (low)
- 10.00
- Target (mean)
- 22.93
- Target (high)
- 48.00
Ratings (0m) 17 12 buy · 4 hold · 1 sell
- Strong buy3
- Buy9
- Hold4
- Sell0
- Strong sell1
Next earnings
Mar 1, 2027
Expected Mar 1, 2027. Consensus EPS estimate -0.13392.
Financials — quick view
BHVN Revenue — quarterly 0
BHVN Net income — quarterly -129.28M
BHVN EPS — quarterly -0.86
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 1, 2027 | Dec 30, 2026 | 0.0671 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | -0.78333 | -0.86 | -0.08 | -9.79% |
| Aug 10, 2026 | Jun 30, 2026 | -0.76098 | -0.91 | -0.15 | -19.58% |
| May 4, 2026 | Mar 31, 2026 | -0.86 | -0.88 | -0.02 | -2.33% |
| Mar 2, 2026 | Dec 31, 2025 | -1.22 | -1.21 | +0.01 | +0.82% |
| Nov 10, 2025 | Sep 30, 2025 | -1.91 | -1.64 | +0.27 | +14.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 23, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Sep 10, 2026 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Sep 8, 2026 | RBC Capital | down | Outperform | Sector Perform |
| Aug 12, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Aug 11, 2026 | RBC Capital | main | Outperform | Outperform |
| Jun 29, 2026 | B of A Securities | down | Neutral | Underperform |
About Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- biohaven.com
News
- Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32
- Biohaven Q3 Adj. EPS $(0.73) Beats $(0.74) Estimate
- Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
- Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade
- Biohaven Presents Preclinical Data For BHV-1420 At American Society Of Nephrology Kidney Week 2026
- Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy
- RBC Capital Maintains Sector Perform on Biohaven, Raises Price Target to $22
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday
- Biohaven Rebounds With FDA Review Date for Rare Disease Drug
Your note
Sign in to keep a note on BHVN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAILEY GREGORY HUGH | Director | Purchase | Nov 12, 2025 | 2,020,070 |
| BUTEN MATTHEW | Chief Financial Officer | Conversion of Exercise of derivative security | Jan 4, 2026 | 195,652 |
| CAR BRUCE | Officer | Conversion of Exercise of derivative security | Jan 4, 2026 | 37,715 |
| CHILDS JOHN W | Director | Purchase | Nov 12, 2025 | 0 |
| CLARK GEORGE C. | Officer | Conversion of Exercise of derivative security | Jan 4, 2026 | 86,978 |
| CORIC VLADIMIR | Chief Executive Officer | Conversion of Exercise of derivative security | Jan 4, 2026 | 3,849,350 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.75% | 13,210,585 | 203.18M | Jun 29, 2026 |
| Montanova Capital LLC | 6.81% | 10,286,937 | 158.21M | Jun 29, 2026 |
| Stifel Financial Corporation | 6.58% | 9,941,165 | 152.90M | Jun 29, 2026 |
| Jupiter Topco LLC | 5.68% | 8,584,675 | 132.03M | Jun 29, 2026 |
| Woodline Partners LP | 5.07% | 7,660,280 | 117.82M | Jun 29, 2026 |
| State Street Corporation | 4.60% | 6,947,034 | 106.85M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.45% | 3,699,312 | 56.90M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.29% | 3,455,073 | 53.14M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.44% | 2,180,096 | 33.53M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.99% | 1,489,215 | 22.90M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.97% | 1,459,506 | 22.45M | Jul 30, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 0.88% | 1,333,088 | 20.50M | Jun 29, 2026 |